December I, 2023

Leslie T. Busby, MD, discusses the shift from dose-dependent chemotherapy to the challenge of managing toxicities in biologic and targeted therapies, which are often erroneously developed using the maximum tolerated dose paradigm.

The required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation.

Significant findings from a number of trials in the lung cancer space will make their way into case reports.

Older patients with stage 4 cancer often prioritize quality of life over survival time, according to recent research findings presented at the 2023 American Society of Clinical Oncology Quality Care Symposium.

New treatments can come with high price tags, and a population-based, retrospective study revealed that fewer than 25% of patients with cancer have a documented conversation about the financial aspects of their treatment.

Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.

The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.